| |  A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care. | |
|
| |  UCLA Health Jonsson Comprehensive Cancer Center researchers and physicians who specialize in treating patients with radiation therapies will present data on the latest radiation oncology research and clinical trial results at the 66th annual American Society for Radiation Oncology (ASTRO) meeting in Washington D.C., Sept. 29 to Oct. 2. | |
|
| |  New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. | |
|
| |  Metastatic cancer can be a devastating diagnosis. The cancer is spreading. It may travel to multiple organs in the body. This could mean more pain and ultimately, death. | |
|
| |  A new paper in the Journal of the National Cancer Institute, published by Oxford University Press, indicates that patients may benefit if doctors stop calling certain early-stage changes to the prostate "cancer" at all. | |
|
| |  By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found that activation of the MYC gene -; a well-known cancer-causing gene -; sets off a cascade of events that leads to both initiation and progression of the disease. | |
|
| |  There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully understood. | |
|
| |  The survival rate of men with prostate cancer who had their entire prostate gland removed immediately after the tumor was detected increased by 17 percentage points compared with those who did not have treatment until the tumor began to cause symptoms. | |
|
| |  Older adults treated for cancer face twice the risk of developing cardiovascular diseases compared to those without cancer. The highest risks are seen in patients with metastatic, hematologic, and lung cancers, especially after chemotherapy. | |
|
| |  CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies. | |
|
| |  A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest. | |
